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Aims To evaluate thoracic aortic dilation in patients with Fabry disease (FD).
Methods
and results
A cohort of 106 patients with FD (52 males; 54 females) from three European centres were studied. The diameter of
the thoracic aorta was assessed at three levels (sinus of Valsalva, ascending aorta, and descending aorta) using echo-
cardiograms and cardiovascular magnetic resonance imaging. Aortic dilation at the sinus of Valsalva was found in
32.7% of males and 5.6% of females; aneurysms were present in 9.6% of males and 1.9% of females. No aortic dilation
was observed in the descending aorta. There was no correlation between aortic diameter at the sinus of Valsalva and
cardiovascular risk factors.
Conclusion Fabry disease should be considered as a cardiovascular disease that affects the heart and arterial vasculature, including
the thoracic aorta. Thus, patients with FD should be closely monitored for the presence, and possible progression
and complications of aortic dilation.
Clinical Trial Registration: Protocol 101/01. Ethics committee, Faculty of Medicine, Lausanne.
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Introduction
Fabry disease (FD) is a rare X-linked lysosomal storage disorder
(LSD) caused by deficiency of the enzyme a-galactosidase
A. This deficiency results in the progressive intracellular deposition
of glycosphingolipids (primarily globotriaosylceramide), particularly
in vascular endothelial and smooth muscle cells, the myocardium,
renal epithelium, and dorsal root ganglion cells.1,2 The condition
is associated with multisystemic manifestations, including left ven-
tricular hypertrophy (LVH), renal failure, and stroke, and may
induce premature death as a result of progressive cardiac, renal,
and central nervous system involvement.1,3,4 Although FD has tra-
ditionally been classified as an LSD, increasing evidence suggests
that the disease should also be regarded as a cardiovascular
disease, affecting the myocardium and arterial vasculature.
The most frequent cardiac finding in FD is a high prevalence of
LVH, usually concentric, which typically develops during or after
the third decade of life.5 Patients with Fabry cardiomyopathy ulti-
mately develop progressive heart failure, mostly due to impaired
LV filling.6 Vascular remodelling has been a consistent finding in
small- and medium-sized arteries in FD. Marked and accelerated
increases in intima–media thickness (IMT) of the radial artery
and the common carotid artery (CCA) have been reported.7,8
Other studies looking at cardiac parameters in small groups of
patients have suggested changes at the level of the thoracic
aorta. Several such studies reported increased aortic root diameter
in males with FD relative to females with FD and historical healthy
controls.9– 12 In addition, dilation and thickening of the thoracic
aorta have been described in a few post-mortem reports.2,13,14
However, it is not clear whether aortic remodelling is a character-
istic feature of FD. The aim of the present study was to assess
structural changes in the aorta in a large cohort of patients with
FD. We hypothesized that FD may predispose to remodelling of
the aorta, which could lead to aortic dilation.
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Methods
This observational study population consisted of 112 consecutive
adults with FD referred to three specialized centres for complete clini-
cal assessments. Index cases were referred because of acroparaesthe-
sia, angiokeratomas, cornea verticillata, or renal failure. Genetic
screening of related family members was undertaken following the
identification of each index case. Informed consent was obtained
from all patients. The Institutional Review Boards for each centre
approved the study.
Patient population
Between 1 October 2000 and 31 December 2005, a total of 112 con-
secutively referred adults with confirmed FD from 34 different families
were evaluated. All patients were 18 years of age or older, no females
were pregnant and no patient was receiving enzyme replacement
therapy at the time of baseline evaluation. All males presented with
the classic form of FD, which was confirmed by the detection of
a-galactosidase A deficiency in leukocytes and plasma.15 In females,
diagnosis was confirmed by genetic analysis.
All patients underwent a baseline assessment that included physical
examination, blood pressure measurement, laboratory blood tests, and
measurements of the thoracic aorta. Measurements of aortic diameter
varied between the three centres. Sixty-six patients underwent trans-
thoracic echocardiography (TTE), 36 patients underwent TTE and car-
diovascular magnetic resonance imaging (MRI), and 10 were assessed
using cardiovascular MRI only. Echocardiographic data from six
patients could not be analysed because of poor cardiac or aortic echo-
genicity. These patients were excluded from the analysis. Thus, 106
patients were eligible for the study.
Procedures and measurements
Transthoracic echocardiography was used to evaluate aortic diameter
at the sinus of Valsalva, interventricular septum (IVS) thickness, and
aortic valve integrity. M-mode and two-dimensional echocardiography
were performed by three experienced ultrasonographers, using com-
mercially available equipment (Acuson Sequoia, Siemens, Forchheim,
Germany, and Toshiba Powervision) with a broadband phased-array
transducer. Measurements were taken in triplicate according to the
American Society of Echocardiography recommendations.16 Offline,
two-dimensional measurements of the aortic root at the sinus of Val-
salva were made at end-diastole. Measurements of the ascending aorta
were performed 2 cm above the sino-tubular junction by M-mode
echocardiography. The aortic valve was examined with M-mode and
two-dimensional echocardiography for the presence of structural
abnormalities and using colour Doppler imaging for the presence of
functional abnormalities. A four-degree classification was used to
quantify aortic regurgitation.17
Cardiovascular MRI was performed using a 1.5-T Philips MRI scanner
(Philips Medical Systems, Amsterdam, the Netherlands) or 1.5-T Symph-
ony scanner (Siemens) using a phase-array cardiac coil. In order to
measure aortic diameters, two sequences were obtained: transverse
single-phase ECG-gated (end-diastolic) breath-hold images of the
thorax with a steady-state free precession (SSFP) sequence (6 mm
slice thickness), and retrospective ECG-gated breath-hold short-axis
cine images (25 frames per cardiac cycle) of the LV outflow tract
(SSFP turbo-field echo sequence). Three experienced radiologists ana-
lysed images on a workstation using commercially available software
to measure the diameters of the sinus of Valsalva (at the same level
as assessed using TTE), ascending aorta, and descending aorta.18
Statistical analysis
All statistical analyses were performed using S-PLUSw 6.2 for
Windows Professional Edition. The relationships between relevant
variables [gender, age, body surface area (BSA), body mass index
(BMI), and blood pressure] and diameters were assessed using multiple
regression analyses. A value of P, 0.05 was considered statistically sig-
nificant. The dimensions used as reference criteria to define normal
and dilated aortic diameters, aneurysms, and normal IVS thickness
are shown in Table 1.18
A paired student’s t-test was used to determine whether TTE and
MRI measurements of aortic diameter at the sinus of Valsalva could
be pooled in order to obtain results with higher statistical power.
The student’s t-test was performed on 36 pairs of measurements.
The resulting P-value of 0.814 indicates that the difference between
TTE and MRI measurements is statistically not significant. The 36
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Table 1 International criteria for defining normal and abnormal dimensions of the aorta and interventricular
septum18,28
Anatomic measurement Dimension (mm)
Female Male
Sinus of Valsalva
Normal diameter 30+3 34+3
Dilation .36 .40
Aneurysm .1.5  predicted valuea .1.5  predicted valuea
Ascending aorta
Normal diameter 26+3 29+3
Dilation .32 .35
Descending aorta
Dilation .28 .28
Abnormal interventricular septum thickness .10 .11
aPredicted value for the upper-normal limit for aortic diameter at the sinuses of Valsalva, in both men and women, was computed as 21 mm/m2  body surface area.
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pairs of measurements that are displayed on Figure 1 confirm that TTE
and MRI results are comparable. For patients with both TTE and MRI
measurements, the mean of the measurements was used in the ana-
lyses, unless otherwise indicated.
Statement of responsibility
The authors had full access to all data and take responsibility for its
integrity. All authors have read and agree to the manuscript as written.
Results
Baseline clinical data are summarized in Table 2. All patients were
Caucasian. In comparison with female patients, males had a lower
BMI and lower levels of total serum, low-density lipoprotein and
high-density lipoprotein cholesterol, a greater BSA and IVS thick-
ness, and a higher serum creatinine level; these differences were
statistically significant. Two males were on dialysis and four
males had functioning kidney grafts. The ejection fraction of the
LV was 50% in all patients, thus excluding the presence of signifi-
cant LV systolic insufficiency (no case of LV dilation).
At baseline, male and female patients had comparable mean sys-
tolic and diastolic arterial blood pressures, and all patients had blood
pressure within normal range (with or without antihypertensive
treatment). Seventeen male (33%) and 13 female (24%) patients
were under antihypertensive therapy: one drug in 20 patients (11
males/9 females), two drugs in 8 (4 males/4 females), and three
drugs in 2 male patients. Antihypertensive treatment included
b-blockers (n ¼ 12; 5 males/7 females), ACEI/ARB (n ¼ 16; 13
males/3 females), diuretics (n ¼ 6; 3 males/3 females), and calcium
channel blockers (n ¼ 8; 4 males/4 females). All other baseline
parameters were also comparable between the genders.
Minor structural changes of the aortic valve (grade 1) were
found in 21 males (40%) and 23 females (43%). One male
patient (aged 45 years) had undergone an aortic valve replacement
5 years previously. This patient had dilation at the sinus of Valsalva.
The aortic valve was bicuspid in one female patient (aged 27 years);
she had a normal aortic diameter.
Abnormal IVS thickening (Table 1) was present in 42 males
(80%) and 31 females (57%).
Thoracic aortic dilation was present at the sinus of Valsalva and
ascending aorta in 32.7% and 29.6% of male patients, respectively.
For male patients, the mean diameters of the thoracic aorta at the
sinus of Valsalva and ascending aorta (Table 3) were significantly
greater than normal (Table 1) (P, 0.001 and P ¼ 0.004, respect-
ively). In females, thoracic dilation at the sinus of Valsalva and
ascending aorta was present in 5.6% (3 of 54 patients) and
21.1% (4 of 19 patients) of patients, respectively. However, for
female patients, the mean diameters at these two levels of the
aorta were within the normal range (P ¼ 0.341 and P ¼ 0.209,
respectively). Dilation at the descending aorta was not observed
in any patient.
Thoracic aortic dilation appeared in male patients at a signifi-
cantly earlier age than in females (Figure 2). The mean age of
patients with dilation at the sinus of Valsalva was 46.8 years
(range, 25–60 years) for males and 69.1 years (range, 55–80
years) for females (P ¼ 0.001). In male patients who were 40
years of age, 35.7% had some degree of aortic dilation at the
sinus of Valsalva; this proportion rose to 55% in males aged 50
years. Aortic dilation was not observed in females ,50 years.
In males, dilation was equally prevalent at the sinus of Valsalva (17
of 52 patients; 32.7%) and ascending aorta (8 of 27; 29.6%) (Table 3).
Concomitant dilations at the sinus of Valsalva and ascending aorta
were observed in five male patients; their age (mean, 48.8 years)
was comparable to that of males with dilation restricted to the
sinus of Valsalva (mean, 46.0 years) (P ¼ 0.441). A total of six
patients [5 of 52 males (9.6%) and 1 of 54 females (1.9%)] had aneur-
ysms at the sinus of Valsalva. In these cases, male patients (mean age,
49.6 years) were younger than the female (80 years of age), a pattern
similar to that seen for aortic dilation. The baseline clinical charac-
teristics of these five male patients were comparable to those of
the male patients without aneurysm, except for IVS thickness
which was significantly increased (P, 0.001). Cardiac MRI data
available for two male patients indicated that both had concomitant
dilation of the ascending aorta.
A multivariate regression analysis was performed to identify
factors that might be linked to aortic dilation at the sinus of Val-
salva (Table 4). Gender (P, 0.0001), age (P ¼ 0.001), and IVS
thickness (P, 0.0001) were strongly associated with dilation of
the sinus of Valsalva. There was no association with serum creati-
nine level. Interventricular septum thickness and BSA were also
found to be correlated with diameters of the sinus of Valsalva
and the ascending and descending aorta. For males, there were
no correlations between systolic or diastolic blood pressure and
aortic diameter at the level of the sinus of Valsalva and ascending
and descending aorta. For females, there was a significant corre-
lation between systolic blood pressure and the diameter of the
sinus of Valsalva (P ¼ 0.008); all other relationships between
blood pressure and aortic diameter were non-significant.
Figure 1 Magnetic resonance imaging (MRI) and transthoracic
echocardiography (TTE) measurements of aortic diameter at
the sinus of Valsalva for 36 patients with Fabry disease. The
student t-test value (P-value ¼ 0.814) confirms that TTE and
MRI results are comparable.
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Interaction between gender and IVS thickness, and between
gender and age, was significant at the level of the sinus of Valsalva
(P ¼ 0.012 and P ¼ 0.019, respectively).
Discussion
The present study provides more evidence for a high prevalence of
ascending aorta dilation and aneurysms in male patients with FD
compared with the normal population. Females with FD also
developed dilation at the sinus of Valsalva and ascending aorta,
but at a significantly lower rate than males, and 15–20 years
later. Dilation appeared to be independent from cardiovascular
risk factors.
The lower prevalence and delayed onset of aortic dilation in
female patients is consistent with previous studies which have
shown that compared with males, females are less prone to devel-
oped major structural arterial change.11,12 It is also in line with the
body of evidence showing that disease severity is generally more
variable and of later onset in females than in males, most probably
as a result of the X-linked manner of inheritance of the con-
dition.3– 5,9 In male patients, dilation of the aorta at the level of
the sinus of Valsalva and ascending aorta was observed in a
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Table 2 Baseline clinical characteristics of the analysed population
Parameters Males (n 5 52)a Females (n5 54)a P-value
Age (years) 39.9+11.7 43.4+17.9 0.236
Height (cm) 173.6+7.2 162.7+5.6 ,0.001
Weight (kg) 67.3+10.8 63.4+10.9 0.069
Body surface area (m2) 1.8+0.16 1.67+0.13 ,0.001
Body mass index (kg/m2) 22.3+3 24+4.5 0.019
Systolic blood pressure (mmHg) 123+12.2 125+16.9 0.485
Diastolic blood pressure (mmHg) 76.8+7.9 76.5+9.6 0.845
Serum total cholesterol (mmol/L) 4.73+1.05 5.5+1.1 ,0.001
Serum HDL cholesterol (mmol/L) 1.43+0.34 1.63+0.43 0.01
Serum LDL cholesterol (mmol/L) 2.72+0.83 3.29+1.02 0.003
Ratio of total to HDL cholesterol 3.45+0.98 3.57+1.07 0.529
Serum triglycerides (mmol/L) 1.22+0.62 1.27+0.53 0.662
Serum creatinine (mmol/L) 125.1+74.2 81.2+17 ,0.001
Patients on dialysis 2 0
Patients with kidney graft 4 0
Interventricular septum (mm) 15.3+4.3 12.2+4.6 0.001
Left ventricular ejection fraction (%) 64.5+7.4 66.1+6.9 0.263
Current smokers, n (%) 9 (17) 5 (9) 0.349
Antihypertensive treatment, n (%) 17 (33) 13 (24) 0.442
Statin therapy 17 (33) 16 (29) 0.422
Diabetes [n (%)] 0 (0) 2 (4) 0.492
aValues expressed as mean+ SD unless otherwise indicated. HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Table 3 Thoracic aorta diameters by gender
Females Males
N Mean+ SD (mm)
(Range)
Number of patients with
aortic dilation [n (%)]
N Mean+ SD (mm)
(Range)
Number of patients with
aortic dilation [n (%)]
Sinus of
Valsalvaa
54 30.8+4.8 (23–51) 3 (5.6) 52 37.9+5.9 (28–55) 17 (32.7)
Ascending
aortab
19 27.1+4.2 (20–34) 4 (21.1) 27 32.3+5.5 (23–43) 8 (29.6)
Descending
aortab
19 19.4+1.7 (16.5–22) 0 27 21.4+2.8 (14–27) 0
SD, standard deviation.
aDiameters measured by transthoracic echocardiography (TTE) and/or cardiac magnetic resonance imaging (MRI); the mean of TTE and MRI was used for 36 patients (21 males) in
whom both measurements were available.
bDiameter measurements for the ascending and descending aorta are available only for 46 patients who underwent cardiac MRI.
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comparable manner, in 32.7% and 29.6% of patients, respectively.
Previous echocardiographic studies in smaller groups of patients
have reported aortic root dilation in 30–56% of males, although
the criteria used to determine dilation vary.9 –12 The observed
values in the present study, which examined unselected patients,
likely represent a more realistic estimate of the prevalence of thor-
acic aortic dilation.
Asymptomatic thoracic fusiform aneurysms, involving two seg-
ments of the aorta as well as the aortic root and ascending
aorta, were found in 9.6% of male patients.19 It is interesting to
note that no patient had aortic dilation and/or aneurysm in the
aortic arch or the descending aorta. Although the number of
patients affected was too small to clearly delineate the risk of
aneurysm, the results suggest that males are at relatively high
risk of developing aortic aneurysms by the fifth decade of life.
The majority of patients with FD who had aortic dilation or
aneurysm were young men, most of whom were either normoten-
sive or had controlled hypertension and had one or more cardio-
vascular risk factors.8,20 Multivariate regression analysis revealed
that gender, age, and IVS thickness were strongly associated with
dilation at the sinus of Valsalva, but that dilation was not associated
with systolic and/or diastolic blood pressure or other cardiovascu-
lar risk factors. In a previous study, we reported the absence of
atherosclerotic plaques in the CCA in patients with FD relative
to a control population among whom 34% were found to have
atherosclerotic plaques.8 These results suggest that the conduit
Figure 2 Box plot of aortic diameters at three thoracic levels (sinus of Valsalva, ascending aorta, and descending aorta) by age and gender.
Box plots include the median (white horizontal line), interquartile range (boxed area), and maximum and minimum scores. Outliers are marked
by a short horizontal line. The horizontal rule in each graph indicates the threshold of dilation for each aortic level and gender (Table 1).
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arteries may be protected from atherosclerosis in FD. Therefore,
atherosclerosis and hypertension do not appear to play a signifi-
cant role in the development of aortic dilation in patients with FD.
Aortic dilation can lead to aortic regurgitation, dissection, and/or
rupture.21,22 However, to the best of our knowledge, aortic dissec-
tion or rupture has not been reported in FD. In patients with
another genetic condition, Marfan syndrome, increased aortic stiff-
ness often leads to early aortic dissection.23 In a recent study,
Kalliokoski et al. reported that carotid, brachial, and aortic IMT
were significantly increased in 17 Fabry patients compared with
34 healthy controls, but no differences were obtained in arterial
compliance (stiffness) between the groups.24 The observation of
an absence of functional aortic changes in Fabry patients, despite
the presence of structural aortic anomalies, may explain why the
risk of aortic dissection could be relatively limited in these patients.
Fabry disease has features (aortic dilation/aneurysm) in common
with Marfan syndrome [ fibrillin-1 (FBN1) gene] and other autoso-
mal dominant disorders, such as Ehlers–Danlos syndrome
(inborn defect of collagen type III, gene COL3A1) and familial
aortic aneurusm/dissection.18,25 In these disorders, weakening of
the aortic wall is mainly caused by cystic medial necrosis.26 This
process is characterized by degeneration of elastic fibres and col-
lagen in the medial layer of the aorta, and subsequent accumulation
of mucoid material. Mutations of the FBN1 and COL3A1 genes may
produce a spectrum of connective tissue disorders that lead to
abnormal or reduced matrix deposition in the aorta and the sub-
sequent development of an aneurysm.
The close correlation between thoracic aortic diameters and IVS
thickness might suggest a common pathogenic mechanism. In a
recent study, we detected a circulating growth-promoting factor
in plasma from patients with FD that leads, in vitro, to both hyper-
trophy and hyperplasia of cardiomyocytes and vascular smooth
muscle cells.20 We observed that the progressive development
of LVH and increasing thickness of the CCA intima–media
occurred concomitantly, and independently of blood pressure.
The correlations between CCA IMT and IVS thickness and
between IVS thickness and aortic diameter suggest that the same
pathogenic mechanism contributes to the development of LVH,
CCA intima–media thickening and thoracic aorta dilation/aneur-
ysm. On the basis of these findings, IVS thickening may be a clini-
cally relevant indicator of thoracic aortic dilation. Our hypothesis is
supported by the work of Aerts et al.27 showing lyso-Gb3 as poten-
tial common growth-promoting factor.
The high prevalence of thoracic aortic dilation and aneurysm in
FD, accompanied by normal blood pressure, indicates that FD
should be treated as a cardiovascular disease in its own right.
Longitudinal follow-up of a large cohort of patients is necessary
to determine the natural history of aortic dilation and evaluate
the risk of serious complications such as dissection and/or
rupture. We suggest, however, that aortic diameter should be
monitored in male patients with FD disease, particularly those
who are aged 40 years or have severe LVH.
This study has certain limitations that should be acknowledged.
We could not obtain all measurements using both echocardio-
graphic and MRI depending on their limited availability in all
centres involved in the study. It was not possible to obtain
measurements of the aortic diameter at the three different levels
in all patients. For defining normal and abnormal dimensions of
the aorta, we used the international criteria and not an age-
matched control group. In a future study, it would be of interest
to examine the natural progression of dilation in greater detail.
In conclusion, the findings of this observational study, which we
believe is the most comprehensive evaluation of thoracic aortic
dilation in patients with FD conducted to date, suggest that the
aortic remodelling process in FD primarily affects the aortic root
and ascending aorta, mainly in male patients. Dilation appears at
a younger age in patients with FD compared with the general
population. As described previously, hypertension and athero-
sclerosis do not appear to be as important in the development
of thoracic aortic dilation in FD as they are in the general popu-
lation. Thus, FD should be included in the list of hereditary diseases
that are associated with ascending thoracic dilation/aneurysm.
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